15-Year Experience of Patch Testing during Pregnancy: Retrospective Case-Control Study from a Tertiary Israeli Center.

IF 3.6 3区医学 Q2 DERMATOLOGY

Dermatology Pub Date : 2026-01-01 Epub Date: 2026-03-12 DOI:10.1159/000551449

Daniel Hilewitz, Akiva Trattner, Yehonatan Noyman, Igal Igor Radinsky, Nuriel Ben Simon, Eran Galili, Shany Sherman, Daniel Mimouni, Igor Snast

{"title":"15-Year Experience of Patch Testing during Pregnancy: Retrospective Case-Control Study from a Tertiary Israeli Center.","authors":"Daniel Hilewitz, Akiva Trattner, Yehonatan Noyman, Igal Igor Radinsky, Nuriel Ben Simon, Eran Galili, Shany Sherman, Daniel Mimouni, Igor Snast","doi":"10.1159/000551449","DOIUrl":null,"url":null,"abstract":"Introduction: Although patch testing (PT) is not contraindicated during pregnancy, most dermatologists defer testing due to lack of data and possibility that immunological changes might influence outcomes. In our center, we routinely perform PT during pregnancy as it is not known to be teratogenic and may lead to significant improvements in quality of life. This study aimed to assess whether pregnancy alters the outcome of PT.Methods: Retrospective, single-center case-control study was conducted at a tertiary Israeli dermatology clinic (2009-2023). Women who gave birth within 40 weeks of PT were identified, and for each, three age-, year-, and atopic dermatitis-matched controls were selected.Results: Of 3,351 women tested, 54 (1.6%) were pregnant at the time of PT. Most were tested during the first trimester (63%). No significant differences were found in the frequency of positive patch test reactions between pregnant women and matched controls. The most common allergens in pregnant patients were nickel sulfate (61.1%), 2-hydroxyethyl methacrylate (13.64%), and fragrance mix II (5.5%).Conclusion: Pregnancy does not appear to affect patch test outcomes in early and mid-gestation. Due to limited third-trimester representation, further studies are needed to determine whether reactivity remains consistent throughout all stages of pregnancy. .","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"365-371"},"PeriodicalIF":3.6000,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13171083/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000551449","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/3/12 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Although patch testing (PT) is not contraindicated during pregnancy, most dermatologists defer testing due to lack of data and possibility that immunological changes might influence outcomes. In our center, we routinely perform PT during pregnancy as it is not known to be teratogenic and may lead to significant improvements in quality of life. This study aimed to assess whether pregnancy alters the outcome of PT.

Methods: Retrospective, single-center case-control study was conducted at a tertiary Israeli dermatology clinic (2009-2023). Women who gave birth within 40 weeks of PT were identified, and for each, three age-, year-, and atopic dermatitis-matched controls were selected.

Results: Of 3,351 women tested, 54 (1.6%) were pregnant at the time of PT. Most were tested during the first trimester (63%). No significant differences were found in the frequency of positive patch test reactions between pregnant women and matched controls. The most common allergens in pregnant patients were nickel sulfate (61.1%), 2-hydroxyethyl methacrylate (13.64%), and fragrance mix II (5.5%).

Conclusion: Pregnancy does not appear to affect patch test outcomes in early and mid-gestation. Due to limited third-trimester representation, further studies are needed to determine whether reactivity remains consistent throughout all stages of pregnancy.

查看原文本刊更多论文

15年妊娠期斑贴试验经验：来自以色列三级中心的回顾性病例对照研究。

背景：虽然斑贴试验（PT）在怀孕期间不是禁忌症，但由于缺乏数据和免疫变化可能影响结果，大多数皮肤科医生推迟了测试。在我们中心，我们经常在怀孕期间进行PT，因为它不知道是致畸的，可能会显著改善生活质量。目的：探讨妊娠是否会改变pt的预后。方法：2009-2023年在以色列一家三级皮肤科诊所进行回顾性、单中心病例对照研究。确定在PT后40周内分娩的妇女，并为每个妇女选择三个年龄，年龄和特应性皮炎匹配的对照。结果：在接受检测的3351名妇女中，54名（1.6%）在PT时怀孕。大多数在妊娠早期进行了检测（63%）。在贴片试验阳性反应的频率在孕妇和匹配的对照组之间没有发现显著差异。孕妇最常见的过敏原为硫酸镍（61.1%）、甲基丙烯酸2-羟乙酯（13.64%）和香精II（5.5%）。局限性：样本量不足以检测低流行过敏原的差异。潜在的推荐和选择偏差限制了普遍性。结论：妊娠不影响早期和中期妊娠斑贴试验的结果。由于孕晚期的代表性有限，需要进一步的研究来确定反应性是否在整个妊娠阶段保持一致。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Dermatology 医学-皮肤病学

CiteScore

6.40

自引率

2.90%

发文量

审稿时长

1 months

期刊介绍： Published since 1893, ''Dermatology'' provides a worldwide survey of clinical and investigative dermatology. Original papers report clinical and laboratory findings. In order to inform readers of the implications of recent research, editorials and reviews prepared by invited, internationally recognized scientists are regularly featured. In addition to original papers, the journal publishes rapid communications, short communications, and letters to ''Dermatology''. ''Dermatology'' answers the complete information needs of practitioners concerned with progress in research related to skin, clinical dermatology and therapy. The journal enjoys a high scientific reputation with a continually increasing impact factor and an equally high circulation.